PT-141 10mg
FDA-approved under the commercial name Vyleesi. One of the most extensively studied peptides in its class, with Phase 2 and 3 clinical data and a unique central nervous system mechanism.
How It Works
The Target
MC3R and MC4R in the hypothalamus — brain receptors that regulate sexual desire and arousal. Unlike PDE5 inhibitors, PT-141 works centrally, not through blood vessel dilation.
The Mechanism
Activates melanocortin-4 receptors in the medial preoptic area of the hypothalamus, triggering dopamine release in pathways associated with sexual motivation. This is a fundamentally different mechanism from vascular approaches — it addresses desire and arousal at the neurological level.
Why It Matters
FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first and only FDA-approved treatment that works through the brain's desire pathways rather than peripheral blood flow.
Specifications
| Purity | >=98% |
| MW | ~1.0 kDa (cyclic) |
| Form | Lyophilized white powder |
| Storage | -20 degrees C |
| Reconstitution | Bacteriostatic water |
| Shelf Life | 24 months |
Published References
Read the research: PT-141 melanocortin MC4R signaling & receptor pharmacology →